Epidermal growth factor receptor tyrosine kinase inhibitors
نویسندگان
چکیده
منابع مشابه
2D-QSAR and docking studies of 4-anilinoquinazoline derivatives as epidermal growth factor receptor tyrosine kinase inhibitors
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor derivatives play an important role in the treatment of cancer. We aim to construct 2D-QSAR models using various chemometrics using 4-anilinoquinazoline-containing EGFR TKIs. In addition, the binding profile of these compounds was evaluated using a docking study. Materials and Methods: In this study, 122 compounds of...
متن کاملRegulatory control of the epidermal growth factor receptor tyrosine kinase.
The epidermal growth factor (EGF) receptor has been shown to posses an intrinsic tyrosine protein kinase activity that is stimulated by the binding ofEGF [1]. In addition, two other ligands for the EGF receptor can stimulate the tyrosine protein kinase activity in intact cells: TGF-(X (transforming growth factor (X) and a soluble biosynthetic precursor of TGF-(X [2, 3]. Analysis of the kinetics...
متن کاملCalmodulin inhibits the epidermal growth factor receptor tyrosine kinase.
We demonstrate in this report that the epidermal growth factor (EGF) receptor from rat liver can be isolated by calmodulin affinity chromatography by binding in the presence of Ca2+ and elution with a Ca(2+)-chelating agent. The bulk of the EGF receptor is not eluted by a NaCl gradient in the presence of Ca2+. We ascertained the identity of the isolated receptor by immunoblot and immunoprecipit...
متن کاملEpidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
PURPOSE EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. METHODS This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. RESULTS The discovery of EGFR mutations has a...
متن کاملSensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
Most patients with non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR-TKI), and their sensitivities to various EGFR-TKI have been well characterized. Our previous article showed the in vitro sensitivities of EGFR exon 18...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2004
ISSN: 0007-0920,1532-1827
DOI: 10.1038/sj.bjc.6601873